{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:55:45Z","timestamp":1790286945597,"version":"4.1.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:p>Immunotherapy targeting the programmed cell death 1 (PD-1) receptor has demonstrated tremendous promise in the treatment of advanced solid tumors. Dermatologic toxicities, however, are an emerging consequence of this therapy and have been clearly associated with immune checkpoint blockade antibodies. Distinctive clinical and histologic subtypes of dermatologic toxicity secondary to immunotherapy are emerging and include rare autoimmune bullous reactions (eg, bullous pemphigoid) and lichenoid eruptions. We report three patients who developed lichenoid dermatitis while receiving anti-PD-1 antibody therapy. The mean time to onset of lichenoid dermatologic toxicity was 42 days (range: 1\u201375 days) from initiation of anti-PD-1 antibody therapy. Lesions most frequently presented on the extremities and trunk as pustules, papules, and plaques. The face was not commonly involved. Of the five skin biopsies examined, all demonstrated dense band-like lymphocytic infiltrate, hyperkeratosis, hypergranulosis, saw-tooth rete ridge pattern, and dyskeratosis. Acanthosis was a feature in all of the skin biopsies, and in one, epidermal hyperplasia was prominent. In several skin biopsies, histologic features supporting a lichenoid drug eruption were present, including parakeratosis, spongiosis, periadnexal\/perivascular inflammation, and eosinophils. Furthermore, the histologic features varied in skin biopsy specimens taken from the same patient at different sites, supporting a drug reaction. All patients' skin lesions improved with use of steroids: two were treated with topical steroids and one with systemic steroids. Recognition of the histopathologic patterns of dermatologic toxicities resulting from immune checkpoint blockade therapy will become increasingly important for ensuring appropriate management of dermatologic toxicities and optimal patient care.<\/jats:p>","DOI":"10.1097\/dad.0000000000000688","type":"journal-article","created":{"date-parts":[[2017,2,10]],"date-time":"2017-02-10T06:33:39Z","timestamp":1486708419000},"page":"121-129","source":"Crossref","is-referenced-by-count":102,"title":["Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features"],"prefix":"10.1097","volume":"39","author":[{"given":"Michael T.","family":"Tetzlaff","sequence":"first","affiliation":[{"name":"Department of Pathology, Section of Dermatopathology, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyadharsini","family":"Nagarajan","sequence":"additional","affiliation":[{"name":"Department of Pathology, Section of Dermatopathology, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Chon","sequence":"additional","affiliation":[{"name":"Dermatology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auris","family":"Huen","sequence":"additional","affiliation":[{"name":"Dermatology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Diab","sequence":"additional","affiliation":[{"name":"Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pacha","family":"Omar","sequence":"additional","affiliation":[{"name":"Dermatology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phyu P.","family":"Aung","sequence":"additional","affiliation":[{"name":"Department of Pathology, Section of Dermatopathology, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Torres-Cabala","sequence":"additional","affiliation":[{"name":"Department of Pathology, Section of Dermatopathology, The University of Texas MD Anderson Cancer Center, Houston, TX;"},{"name":"Dermatology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Mays","sequence":"additional","affiliation":[{"name":"Dermatology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor G.","family":"Prieto","sequence":"additional","affiliation":[{"name":"Department of Pathology, Section of Dermatopathology, The University of Texas MD Anderson Cancer Center, Houston, TX;"},{"name":"Dermatology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Curry","sequence":"additional","affiliation":[{"name":"Department of Pathology, Section of Dermatopathology, The University of Texas MD Anderson Cancer Center, Houston, TX;"},{"name":"Dermatology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230908","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med."},{"key":"R2-20230908","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2014.58.3708","article-title":"Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer","volume":"33","author":"Gettinger","year":"2015","journal-title":"J Clin Oncol."},{"key":"R3-20230908","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med."},{"key":"R4-20230908","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol."},{"key":"R5-20230908","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.2217\/fon.15.118","article-title":"Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis","volume":"11","author":"Abdel-Rahman","year":"2015","journal-title":"Future Oncol."},{"key":"R6-20230908","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2014","journal-title":"N Engl J Med."},{"key":"R7-20230908","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1001\/jamadermatol.2015.5210","article-title":"Inverse psoriasiform eruption during pembrolizumab therapy for metastatic melanoma","volume":"152","author":"Totonchy","year":"2106","journal-title":"JAMA Dermatol."},{"key":"R8-20230908","doi-asserted-by":"crossref","DOI":"10.1111\/cup.12717","article-title":"Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions","author":"Jour","year":"2016","journal-title":"J Cutan Pathol."},{"key":"R9-20230908","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/CMR.0000000000000191","article-title":"Acute skin reaction suggestive of pembrolizumab-induced radiosensitization","volume":"25","author":"Sibaud","year":"2015","journal-title":"Melanoma Res."},{"key":"R10-20230908","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/CMR.0000000000000155","article-title":"A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab","volume":"25","author":"Carlos","year":"2015","journal-title":"Melanoma Res."},{"key":"R12-20230908","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaad.2008.09.032","article-title":"Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists","volume":"61","author":"Asarch","year":"2009","journal-title":"J Am Acad Dermatol."},{"key":"R13-20230908","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s13555-012-0003-9","article-title":"GA101 (a novel anti-CD20 monoclonal antibody)-induced lichenoid eruption","volume":"2","author":"Bakkour","year":"2012","journal-title":"Dermatol Ther."},{"key":"R14-20230908","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1634\/theoncologist.2014-0169","article-title":"Lichenoid mucosal reaction to rituximab","volume":"19","author":"Kuten-Shorrer","year":"2014","journal-title":"Oncologist"},{"key":"R15-20230908","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/2326-6066.CIR-14-0134","article-title":"Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy","volume":"3","author":"Joseph","year":"2015","journal-title":"Cancer Immunol Res."},{"key":"R16-20230908","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol."},{"key":"R17-20230908","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/cup.12666","article-title":"Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy","volume":"43","author":"Schaberg","year":"2016","journal-title":"J Cutan Pathol."},{"key":"R18-20230908","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jaad.2015.10.029","article-title":"Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort","volume":"74","author":"Hwang","year":"2016","journal-title":"J Am Acad Dermatol."},{"key":"R19-20230908","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/j.jaad.2012.12.963","article-title":"The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis","volume":"69","author":"Minkis","year":"2013","journal-title":"J Am Acad Dermatol."},{"key":"R20-20230908","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1158\/1078-0432.CCR-06-2318","article-title":"A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer","volume":"13","author":"Small","year":"2007","journal-title":"Clin Cancer Res."},{"key":"R21-20230908","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1","volume":"4","author":"Naidoo","year":"2016","journal-title":"Cancer Immunol Res."}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000372-201702000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:07:58Z","timestamp":1694131678000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000372-201702000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000000688","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727255253.793529378","asserted-by":"object"}]},"ISSN":["0193-1091"],"issn-type":[{"value":"0193-1091","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]}}}